Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.
Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 4 September 2020.
In the spotlight this week are new trial results in the SGLT2 inhibitor and cardiovascular spaces, antibodies in development for COVID-19, and how the pandemic is affecting consumers' perceptions of healthcare.
Stories mentioned in this episode:
(Also see "DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front" - Scrip, 31 Aug, 2020.)
(Also see "Heart Failure A Key Future Market For Jardiance?" - Scrip, 2 Sep, 2020.)
(Also see "As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran" - Scrip, 1 Sep, 2020.)
(Also see "Regeneron and Roche Await Data On Potential COVID-19 Blockbuster" - Scrip, 3 Sep, 2020.)
(Also see "Post-COVID-19 Consumer Preferences A Guide For Pharma Strategy" - Scrip, 31 Aug, 2020.)